You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study

Citation Tools

Article menu

Download PDFPDF

Thursday 06 October 2022 from 15:40 to 17:10
S11 immune system in SLE
S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Van Vollenhoven R, Pike M, Merrill J, et al
S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study
Lupus Science & Medicine 2022;9:doi: 10.1136/lupus-2022-elm2022.23